US 12,286,470 B2
Methods of determining the function of polyubiquitin using anti-polyubiquitin antibodies
Robert F. Kelley, Petaluma, CA (US); Vishva Dixit, Los Altos, CA (US); and Marissa L. Matsumoto, Foster City, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Jan. 26, 2023, as Appl. No. 18/159,728.
Application 18/159,728 is a division of application No. 16/914,996, filed on Jun. 29, 2020, granted, now 11,597,761.
Application 16/914,996 is a division of application No. 15/071,422, filed on Mar. 16, 2016, granted, now 10,738,106, issued on Aug. 11, 2020.
Application 15/071,422 is a division of application No. 13/567,919, filed on Aug. 6, 2012, granted, now 9,321,844, issued on Apr. 26, 2016.
Claims priority of provisional application 61/515,729, filed on Aug. 5, 2011.
Prior Publication US 2023/0348581 A1, Nov. 2, 2023
Int. Cl. C07K 16/18 (2006.01); C07K 16/40 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [C07K 16/40 (2013.01); G01N 33/68 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. A method of determining the function and/or activity of C- to N-terminal-linked polyubiquitin in a cell or sample comprising contacting the cell or sample with at least one antibody and assessing the effect of said contacting step on the cell or sample, wherein the at least one antibody comprises:
a) the hypervariable (HVR)-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 58, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 82, and the HVR-H3 sequence of SEQ ID NO: 9; or
b) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence selected from SEQ ID NO: 2, 58 and 60, the HVR-L3 sequence selected from SEQ ID NO: 3, 65 and 72, the HVR-H1 sequence of SEQ ID NO: 7 or 80, the HVR-H2 sequence of SEQ ID NO: 8 or 82, and the HVR-H3 sequence of SEQ ID NO: 9 or 87: or
c) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 58, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 9: or
d) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 82, and the HVR-H3 sequence of SEQ ID NO: 9: or
e) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 10, the HVR-H2 sequence of SEQ ID NO: 11, and the HVR-H3 sequence of SEQ ID NO: 12: or
f) the HVR-L1 sequence of SEQ ID NO: 19, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 10, the HVR-H2 sequence of SEQ ID NO: 23, and the HVR-H3 sequence of SEQ ID NO: 12: or
g) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 20, the HVR-H1 sequence of SEQ ID NO: 10, the HVR-H2 sequence of SEQ ID NO: 11, and the HVR-H3 sequence of SEQ ID NO: 12; or
h) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 21, the HVR-H1 sequence of SEQ ID NO: 22, the HVR-H2 sequence of SEQ ID NO: 24, and the HVR-H3 sequence of SEQ ID NO: 12: or
i) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 9; or
j) the HVR-L1 sequence of SEQ ID NO: 4, the HVR-L2 sequence of amino acids 50-56 of SEQ ID NO: 27, the HVR-L3 sequence of SEQ ID NO: 5, the HVR-H1 sequence of SEQ ID NO: 13, the HVR-H2 sequence of amino acids 52-62 of SEQ ID NO: 31, and the HVR-H3 sequence of SEQ ID NO: 15: or the HVR-L1 sequence of SEQ ID NO: 4, the HVR-L2 sequence of amino acids 50-56 of SEQ ID NO: 28, the HVR-L3 sequence of SEQ ID NO: 6, the HVR-H1 sequence of SEQ ID NO: 16, the HVR-H2 sequence of amino acids 52-62 of SEQ ID NO: 32, and the HVR-H3 sequence of SEQ ID NO: 18: or
k) the HVR-L1 sequence of SEQ ID NO: 1, 50, 52-57, or 199-218, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 9; or
l) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 58-62 or 219-239, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 9; or
m) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 6, 64-72, or 240-254, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 9; or
n) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 73-81 or 255-260, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 9, or
o) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 17, 82-86, or 261-264, and the HVR-H3 sequence of SEQ ID NO: 9; or
p) the HVR-L1 sequence of SEQ ID NO: 1, the HVR-L2 sequence of SEQ ID NO: 2, the HVR-L3 sequence of SEQ ID NO: 3, the HVR-H1 sequence of SEQ ID NO: 7, the HVR-H2 sequence of SEQ ID NO: 8, and the HVR-H3 sequence of SEQ ID NO: 265-282.